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Lipid membraneantimicrobial peptide PFWRIRIRR in bacteria utilizing production in the form of
insoluble fusion protein with ketosteroid isomerase. The recombinant peptide was rapidly and efﬁciently
isolated by acidic cleavage of the fusion protein based on the acid labile Asp–Pro bond at the N-terminus of
the peptide. The peptide has antibacterial activity and neutralizes macrophage activation by LPS. The
selectivity of the peptide against bacteria correlates with preferential binding to acidic phospholipid vesicles.
Solution structure of the peptide in SDS and DPC micelles was determined by NMR. The peptide adopts a
well-deﬁned structure, comprising a short helical segment. Cationic and hydrophobic clusters are segregated
along the molecular axis of the short helix, which is positioned perpendicular to the membrane plane. The
position of the helix is shifted in twomicellar types and more nonpolar surface is exposed in anionic micelles.
Overall structure explains the advantageous role of the N-terminal proline residue, which forms an integral
part of the hydrophobic cluster.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Treatment of bacterial infection with antibiotics is one of the
mainstays of medicine [1]. Increasing resistance of virtually all
microbes toward common antibiotics is a major health concern.
Antimicrobial peptides are present in a variety of organisms where
they protect the host from microbial infection. They have been
identiﬁed in and isolated from a variety of sources including
mammals, insects, amphibians, ﬁsh, plants, prokaryotes [2,3]. These
peptides are less susceptible to the development of bacterial
resistance because they act on the bacterial membrane causing
multiple stress through several targets [4] but have minimal toxic
and allergic effects to the host [5]. Thus, antimicrobial peptides may
potentially be applied in medicine as safe antimicrobial agents due to
their activities against bacteria and fungi [6]. Recent studies have
shown thatmany cationic antimicrobial peptides are able to neutralize
LPS [7], block cytokine induction in macrophages and prevent sepsis
in animal models. Sepsis due to a Gram-negative bacteria is usually
caused by the release of a bacterial outer membrane component,
endotoxin (lipopolysaccharide, LPS) [7].
In order to provide large quantities of these peptides for
physiological investigation and clinical trials, efﬁcient production
methods are necessary. Short antimicrobial peptides can be efﬁciently
prepared by chemical synthesis, but may still be prohibitively
expensive for therapy [8]. As an alternative, recombinant methods386 1 476 0300.
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Production of antimicrobial peptides in expression systems, such as
bacterial, yeast or insect cells has been reported. Escherichia coli has
been used for production of many antimicrobial peptides, e.g.
lactoferricin [9], dermicin [10], moricidin [11], defensins [12–14] and
buforin [15]. This biological expression system is also suitable to
obtain uniformly or partially isotopically enriched peptides, which are
required for structural investigation of the ligand–receptor interaction
by NMR spectroscopy and provides additional information on
molecular dynamics, improvement of the precision of the determined
structures and ﬁltered experiments in the complex systems [16,17].
However, difﬁculties have been encountered in expression of
antimicrobial peptides because of their cytotoxicity to host cells,
sensitivity to proteolytic degradation and low expression level [18].
The expression system with an antimicrobial peptide fused to a
partner protein is most effective because of the reduced toxicity
against host cells, enhanced product stability and facilitated product
recovery [19]. Such fusion proteins generally lack antimicrobial
activity if they form insoluble products or interact with carrier protein
[20–24]. The peptide is released from the fusion by chemical or
enzymatic cleavage [25].
For this study we selected the peptide based on the structure–
activity development of the peptide LF11 originating from human
lactoferrin We have already reported solution structure of LF11 in
complexwith anionic and zwitterionic amphiphiles [16,26–28], where
LF11 adopted a deﬁned and unique fold in the micellar environment.
We deleted most of the noncharged polar residues that do not
contribute to the favorable interactions with anionic lipids or LPS and
exchanged several residues, which increased its antimicrobial activity
and neutralization of LPS. One of the key properties of antimicrobial
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which is deﬁned but by the peptide structure and target membrane
properties [29]. Importantly, eukaryotic and bacterial membranes
have very different lipid compositions. The membrane of host cells
comprises mainly phosphatidylcholine, sphingomyelin and choles-
terol, whereas bacterial cells expose negatively charged phospholipids,
phosphatidylglycerol, cardiolipin and lipopolysaccharides [30]. As
demonstrated before, a high content of arginine and hydrophobic
residues is essential for activity against bacterial membranes [31].
Short peptides are devoid of deﬁned tertiary structure but can adopt a
deﬁned conformation in the lipid environment.
We have produced and puriﬁed a recombinant antimicrobial
peptide PFWRIRIRR (“PFR peptide”) using ketosteroid isomerase (KSI)
as a fusion partner in E. coli. The fusion protein formed insoluble
inclusion bodies in bacteria. We engineered a single Asp–Pro acid
labile dipeptide between KSI and the PFR peptide, which allowed
efﬁcient production and isolation of the recombinant peptide in
bacteria. We found that the peptide binds to the anionic but not to
zwitterionic lipid vesicles and that the type of lipid mimetics
signiﬁcantly affects the peptide structure and may account for its
antibacterial activity.
2. Materials and methods
2.1. Gene construct preparation
Oligonucleotide (5 ′-phosphate-GATCCGTTCTGGCGTATT
CGCATCCGTCGCTGAATG-3′), the encoding peptide sequence,
annealed with the corresponding complementary oligonucleotide,
was ligated into pET31b (+) expression vector (Novagen) 3′ to the
ketosteroid isomerase (KSI) gene using restriction site AlwN I [32].
2.2. Media and culture conditions
For protein expression, the E. coli BL21 (DE3) pLysS (Invitrogen)
transformed with pET31b(+) encoding KSI–PFR gene and was grown
in TB medium. Fermentation was performed in shake ﬂasks with
100 μg/ml ampicillin at 37 °C and 220 rpm. Measuring the optical
density at 600 nm monitored cell growth. When cultures reached an
OD600 of 0.8, IPTG at 0.4 mM ﬁnal concentration was added to the
culture broth for induction of the production of recombinant KSI–PFR
protein. Four hours after induction, bacteria were harvested by
centrifugation at 700 rpm for10 min.
2.3. Puriﬁcation of the expressed proteins
To purify the recombinant proteins, the cell pellet was suspended
in the lysis buffer (10mMTris pH 8.0,1 mM EDTA, 0.1% DOC) and lysed
by sonication. The bacterial lysate was centrifuged at 12000 rpm for
15 min at 4 °C to separate the soluble supernatant and insoluble pellet
fraction containing inclusion bodies. The insoluble inclusion body
fraction containing KSI–PFR fusion proteins was washed with a series
of wash buffers (10 mM Tris pH=8.0, 1 mM EDTA, 0.1% DOC, twice;
10 mM Tris pH=8.0, 1 mM EDTA, 0.1% DOC, 2 M urea, twice and with
20 mM Tris pH=8.0 three times). After every wash the mixture was
centrifuged at 12,000 rpm for 10 min at 4 °C. The insoluble inclusion
bodies were dissolved in 6 M guanidine–HCl and centrifuged. Soluble
supernatant dialyzed against deionized water that caused precipita-
tion of KSI–PFR. Fusion proteins were resuspended in 90 mM HCl, the
suspension was mixed for 2 h at 85 °C to cleave the aspartyl–prolyl
bond between the KSI segment and recombinant peptide. The peptide
was puriﬁed by HPLC on a C5 RP-HPLC column (Supelco) using a
gradient of 5% acetonitrile, 5 mM HCl and 95% acetonitrile and 5 mM
HCl and freeze dried using repeated washes with water. The peptide
peak was detected by UV absorbance at 280 nm. The identity of the
peptide peak was determined by mass spectrometry.2.4. Peptide synthesis
The PFR peptide was chemically synthesized by KECK center (Yale
University, New Haven, CT, USA) using Fmoc chemistry. The purity of
the synthetic peptide was determined by HPLC and MS analysis.
2.5. Assay of antimicrobial activity
The antibacterial activity of the puriﬁed recombinant PFR was
compared to that of the synthetic peptide, using E. coli (NCTC 8007,
serotype 0111 K58 H2) that was provided by Prof. Ignacio Moriyon,
University of Navarra Pamplona, Spain. Bacterial cultures were stored
at −80 °C and grown on minimal medium at 37 °C. Antimicrobial
activity was determined using standard microbroth dilution assay in
minimal medium.
2.6. Inhibition of NO production in LPS-stimulated RAW264.7macrophages
The RAW264.7 macrophage cell line was cultured in RPMI
supplemented with antibiotic (penicillin 100 IU/ml and streptomycin
100 μg/ml; Gibco) and 12% fetal bovine serum (Perbio) at 37 °C under
5% CO2. The cell suspension of 1 million cells/well and 100 μM
carboxy-PTIO (Sigma) was treated with either LPS (100 ng/ml) alone
or with various concentrations of PFR (10–100 μg/ml) for 24 h. Nitric
oxide was measured as its end product using Griess reagent (Sigma).
The 100 μl culture supernatant from the culture of RAW264.7 cells was
mixedwith an equal volume of Griess reagent and the absorbancewas
measured at 570 nm [33].
2.7. Preparation of unilamellar vesicles
Large unilamellar lipid vesicles (LUVs) used for ITC and ﬂuores-
cence experiments were prepared by extrusion method using a Mini-
Extruder (Avanti Polar lipids Inc.). The multilamellar vesicle suspen-
sion was freeze–thawed for 5 cycles and then extruded 10 times
through polycarbonate ﬁlters (0.1 μm).
2.8. Fluorescence spectroscopy
Tryptophan ﬂuorescencewasmeasured using a Perkin-Elmer LS 55
luminescence spectrometer. Either 1 mM POPG or 1 mM POPC was
introduced to 12 μM peptide in PBS. The excitation wavelength used
was 295 nm and the emission scanned from 300–450 nmwith a scan
speed of 300 nm/s. Fluorescence quenching experiments were
performed by stepwise addition of acrylamide from stock solution of
1 M into peptide containing solutions in the absence or presence of
vesicles at peptide/lipid molar ratio 1:140. Emission spectra, as
previously described, were collected after each addition of quencher
up to the ﬁnal acrylamide concentration of 0.5 M. The data were
analyzed according to the Stern–Volmer equation, F0/F=1+KSV [Q],
where F0 and F are the ﬂuorescence intensities in the absence and the
presence of the quencher (Q) and KSV is the Stern–Volmer quenching
constant, providing ameasure for the accessibility of Trp to acrylamide.
2.9. Determination of haemolytic activity
Heparin (4 μl at 5000 IU/ml)was added to 100 μl of fresh peripheral
blood froma healthy volunteer and centrifuged at 2000 rpm for 10min
at room temperature. We washed the pellet of red blood cells with
phosphate-buffered saline (PBS) and prepared a 2% (vol/vol) suspen-
sion of erythrocytes in PBS. Fifty microliters of the peptide in the
concentration range from10−6 to 10−4M in PBS and50 μl of erythrocyte
suspension were incubated at 37 °C for 1 h. For a positive control, we
used 2% (vol/vol) Triton X-100 in PBS, which caused 100% hemolysis.
After the incubation, samples were centrifuged for 5 min at 2200 rpm
at room temperature, and absorbance at 405 nmwas measured.
Fig. 1. SDS-PAGE analysis of protein production in bacteria. Lanes 1 and 2 represent total
bacterial lysate of non-induced bacteria (1) and bacteria 4 h after IPTG induction (2).
Lane 3 represents inclusion bodies after puriﬁcation. Proteins were stained with
Coomassie brilliant blue.
Fig. 2. Time dependence of peptide cleavage from fusion protein. The fusion protein
KSI–PFR was suspended in diluted acid (90 mM HCl) and mixed at 85 °C to cleave the
aspartyl–prolyl bond between the fusion protein and peptide.
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ITC data were acquired using a VP-ITC calorimeter (Microcal, LLC).
Samples were prepared with 20 μM peptide and either 5 mM POPG or
POPC in 10 mM Tris pH 7 and 100 mMNaCl. To account for the heat of
dilution titrating the lipid vesicles into a buffered solution in the
absence of peptide completed the control experiments. All experi-
ments were carried out at 20 °C. Titration was carried out over a
170 min period, with 300 s between individual 5 μl injections.
2.11. Nuclear magnetic resonance (NMR) spectroscopy
PFR in SDS samplewas prepared by dissolving 1.2mg of the peptide
in 500 μl of sodium phosphate buffer which contained 232 mM D25-
sodium-dodecylsulphate and 8% D2O. The pH was adjusted to 5.5. PFR
peptide in DPC was prepared by dissolving 1.1 mg of the peptide in
460 μl of sodium phosphate buffer that contained 200 mM of D38-
dodecylphosphocholine. 40 μl of D2O was added to the sample and pH
was adjusted to 5.1. The ﬁnal peptide concentration was 1.8 mM. A
sample of 15N-labeled recombinant PFR in SDS was prepared by
dissolving 0.4mg of PFR in 300 μl of sodium phosphate buffer solution,
which contained 127mMd25-SDS and 8% D2O. Spectra were recorded
at 30 °C on aVarianUnity INOVA600MHz spectrometer equippedwith
5 mm 1H(13C/15N) Pulse Field Z-Gradient Triple Probe. 2-D homo-
nuclear TOCSY and NOESY spectra were acquired using WET [34] or
WATERGATE [35] suppression scheme. TOCSY spectrawere recorded at
mixing times of 10 and 80ms. NOESY spectra were recorded at mixing
times of 80 and 150 ms. 2048×256 data points and spectral widths of
8000 Hz in both dimensions were used with 48 to 128 transients. The
HSQC spectrum was acquired with 2048×256 data points. WURST80
decoupling was used to remove coupling from NH protons. Spectra
were assigned using Felix (Acclerys) software. Calibration of volumes
and conversion of volumes into DYANA restraints for upper bounds
was achieved using nmr2st program [36]. Two well resolved aromatic
proton crosspeaks of I5: HG11-I5: HG12 and I7: HG11-I7: HG12 wereused for calibration. The experimental distance constraints were then
employed to generate peptide conformers using 6000 steps of
simulated annealing in torsion angle space implemented in the
program DYANA version 1.5 [37]. 20 structures with the lowest target
function out of 100 calculated structures were kept for further
minimization. Program DISCOVER (Accelrys) using the cvff force ﬁeld
(21) was used to energy minimize the structures. The quality of
structures was checked with PROCHECK_NMR [38]. Structures were
visualized and analyzed with MOLMOL [39].
3. Results
3.1. Production of recombinant antimicrobial peptide in bacteria
Short peptides can be overexpressed in bacteria in the form of
fusion proteins, where both bacteria and peptide are protected from
membranolytic and proteolytic activity, respectively. The peptide is
usually released from the fusion protein by chemical cleavage using
CNBr or hydroxylamine, which can however due to their reactivity
cause formation of unwanted side products [40–43]. Therefore we
have designed a fusion protein of a PFR peptide with ketosteroid
isomerase (KSI–PFR) where we have utilized the acid sensitivity of the
Asp–Pro bond engineered at the N-terminus of the peptide. This bond
is cleaved in diluted acid at rates at least 100 times more efﬁcient than
other peptide bonds. Selective hydrolysis of aspartyl bonds involves
intramolecular catalysis by aspartic carboxylate attack of the sub-
sequent carbonyl group with simultaneous donation of a proton to the
peptide bond nitrogen and consequent anhydride formation resulting
in peptide bond cleavage [40–43]. The recombinant fusion proteinwas
expressed in high yield in E. coli and accumulated in the form of
inclusion bodies. Approximately 550 mg of pure recombinant protein
was obtained from 1 l of culture medium. On SDS-PAGE this is seen as
a band around the molecular weight of 14 kDa, as expected for the
recombinant protein KSI–PFR (Fig. 1).
3.2. Cleavage of the fusion protein at acidic pH
Different conditions were examined to cleave the bond between
the fusion protein and recombinant peptide. Fusion protein was
treated with 60 to 90 mM HCl for various times to cleave the Asp–Pro
bond between the KSI carrier protein and peptide. Alternatively,
protein was dissolved in guanidine–HCl acidiﬁed by formic acid. The
highest amount of the peptide was produced by treatment with
Fig. 3. Reverse-phase HPLC puriﬁcation of recombinant PFR peptide after cleavage of the
KSI–PFR. Peak eluting at 7 min represents the puriﬁed peptide. Magniﬁed inset shows
the difference in elution between synthetic amidated PFR peptide (a) and synthetic and
recombinant PFR (b), which elute at identical retention time. Peptide was eluted by a
gradient from 0 to 95% acetonitrile and 5 mM HCl within15 min.
Fig. 5. Recombinant PFR peptide inhibits LPS stimulated NO production by murine
macrophages. Macrophages were stimulated with 100 ng/ml of LPS in the presence of
varying peptide concentrations and nitrite was determined in the supernatants using
Griess reaction. Data points represent standard errors of the means of the results
obtained from three experiments. The asterisks indicate a signiﬁcant decrease in nitrite
level compared to the results obtained with cells treated with LPS only (Pb0.05).
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ﬁnal yield was 10 mg of puriﬁed peptide from 550 mg of recombinant
protein per liter of bacterial culture. Following the cleavage, the
reaction mixture was puriﬁed by HPLC (Fig. 3). As can be seen, most of
the KSI remained insoluble and the peptide represented more than
80% of the material eluted from the column. Mass spectroscopy was
used to verify the identity of the puriﬁed peptide and its labeling in
15N isotopically enriched minimal medium (Fig. 4). Polypeptide
backbone of the isotopically labeled peptide has been assigned (data
not shown) and will be used to measure interaction of peptide with
bacteria and investigate dynamic properties of the peptide.
3.3. Biological activity of the peptide
Antimicrobial activity of peptide was examined against E. coli. All
tested peptide variants inhibited bacterial growth. The minimal
inhibitory concentration for the recombinant peptide was 18±2 μg/
ml in comparison to 6±3 μg/ml and 48±3 μg/ml for the amidated and
nonamidated synthetic peptide, respectively. Amidation increased the
net charge of the peptide and its afﬁnity to anionic lipids, which is
probably the reason for higher antimicrobial activity of amidatedFig. 4. Mass spectroscopic analysis of the recombinant peptide prepared in bacteria (a), 15
molecular weight of peptides is 1299.5 (a), 1321.5 (b) and 1299.5 (c).peptide. However despite using the same puriﬁcation procedure and
the same MS spectra (Figs. 3 and 4) recombinant peptide was
consistently more active than synthetic peptide, probably because of
some contaminant from the synthesis although the precise reason
could not be determined. Neither recombinant nor synthetic peptides
were hemolytic to human erythrocytes up to concentration of 500 μg/
ml. Peptides based on human lactoferrin have previously shown
neutralization of bacterial endotoxin, which prevents the cellular
activation of macrophages by LPS. To determine the inhibitory effect of
the peptide on nitric oxide production in LPS stimulatedmacrophages,
cells were treated with LPS and different concentrations of recombi-
nant peptide. NO production was assayed by measuring nitrite (a
stable degradation product of NO) in the supernatant of cultured
RAW264.7 cells. Recombinant peptide did not activate the cells, which
indicates the absence of LPS contamination andwas able to inhibit cell
activation by LPS (Fig. 5).N uniformly enriched recombinant peptide (b) and synthetic peptide (c). Theoretical
Fig. 6. Differences in synthetic PFR peptide (top, PFR and bottom, amidated PFR peptide)
interactionwith anionic and zwitterionic phospholipid vesicles determined by intrinsic
tryptophan ﬂuorescence. Fluorescence emission spectra of 12 μMPFR in PBS buffer were
determined in (a) buffer only, (b) 1 mM POPC and (c) 1 mM POPG.
Fig. 7. Stern–Volmer plots for the quenching of Trp ﬂuorescence emission of synthetic
PFR peptide (top) and synthetic amidated PFR peptide (bottom) by acrylamide in a
buffer (□) and in the presence of liposomes composed of POPC (●) and POPG (▲).
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Negatively charged POPG vesicles were used to mimic bacterial
membranes and zwitterionic POPC as eukaryotic membranemimetics.
The ﬂuorescence emission spectra of PFR in the presence of POPG and
POPC are shown in Fig. 6. Binding of the peptide to vesicles caused
15 nm blue shift in the emission maximum for POPG vesicles, while
the emissionmaximumof the peptide in the presence of POPC vesicles
remained essentially unchanged. Blueshift in the presence of POPG
was accompanied by an increase in the ﬂuorescence intensity,
consistent with partitioning of the Trp side chain into a more
hydrophobic environment [44]. Both amidated and nonamidated
peptide displayed a similar effect of different membrane mimetics.
3.5. Fluorescence quenching of intrinsic peptide ﬂuorescence in different
types of environment
In order to investigate the extent of the exposure of tryptophan
residue to the solvent, a ﬂuorescence-quenching study was performed
using a neutral quencher acrylamide. In the presence of acrylamide
the Trp ﬂuorescence emission of the synthetic PFR peptide in an
aqueous buffer decreased in a concentration dependant manner,yielding a Stern–Volmer constant of 28.4 M−1 (Fig. 7). In the presence
of POPC the KSV decreased to 18.1 M−1 and further to 6.3 M−1 for POPG
vesicles. A lower KSV indicates a greater degree of protection of the Trp
residue and indicates that the ﬂuorophore is inserted into the
hydrophobic core of the bilayer. In the case of POPC liposomes the
Trp residue was more accessible to the quencher indicating weaker
interaction and membrane insertion into the membrane. Amidated
peptide however showed an increased degree of protection also in the
presence of POPC micelles, which indicates deeper burial of the
tryptophan residue within the lipid layer. Described results therefore
indicate three different types of environment of the peptide
tryptophan residue: it is protected against quenching in both types
of lipids (more so in POPG), while as opposed to POPC the Trp side
chain is in a more apolar environment in POPG. A likely explanation is
that tryptophan inserts into the hydrophobic core of POPG vesicles
while burial in case of POPC requires the presence of C-terminal
amidation, whereas in case of nonamidated peptide it may only
associate with surface headgroup region of POPC vesicles.
3.6. Isothermal calorimetric titration of peptidewith phospholipid vesicles
The use of ITC provided an opportunity to determine whether the
difference in interactions between neutral and negative lipids would
be detectable and reﬂected by isothermal titration calorimetry [44].
Fig. 8. Binding of synthetic PFR peptide to POPG vesicles determined by isothermal
calorimetry. (a) A representative liposome titration assay obtained for PFR peptide
(20 μM) titrated with 5 μl of 5 mM POPG in 10 mM Tris pH 7 and 100 mM NaCl. (b) The
enthalpy changes for each titration data point.
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POPC vesicles into the peptide solution. The result of the interaction of
the peptide to POPC indicated that the energy change was below theFig. 9. Secondary chemical shifts for Hα protons of synthetic PFR peptide in SDS micelles (le
consecutive residues.sensitivity limit of the technique (data not shown). Binding of the
peptide to POPG is shown in Fig. 8. The binding enthalpy indicates that
peptide interaction with POPG vesicles is an exothermic process. Best
ﬁt was obtained with two binding site equation yielding K1=4.7⁎10+
7 in K2=4.1⁎10+5 M−1. Reaction stoichiometry was estimated at a
lipid to peptide ratio of 21 and 36 for the ﬁrst and second step. First
step indicates a signiﬁcant entropic contribution, probably due to the
penetration of the peptide into the hydrophobic core of the
membrane. Isothermal titration of peptide to lipids has been observed
before and has been attributed to membrane processes such as pore
formation ormembrane disruption have been proposed [45], although
it could also be due to the formation of the second layer of bound
peptide at higher peptide:lipid ratios.
3.7. Structure of peptide in micellar environment
3.7.1. Structure of PFR peptide in SDS micelles
NMR crosspeak assignments of themost active, synthetic amidated
PFR peptide were made using a combination of 2D-TOCSY and 2D-
NOESY spectra. Most crosspeaks were resolved in the ﬁngerprint
region of the NOESY spectrum except an overlap between Arg8 and
Arg9 HN–Hα resonances. HN chemical shifts were in the range between
7.46 and 8.44 ppm. The chemical shift of Phe2 Hα and HN resonances
were 4.69 and 8.44. Only 2D NOESY spectra were determined for
recombinant PFR in SDS and showed high similarity with amidated
synthetic peptide. Secondary chemical shift, Δδ, was calculated for Hα
atoms as the difference between the random coil chemical shift, δRC,
and the measured chemical shift δmeasured [46]. Secondary chemical
shifts of the Hα resonances contain the information on the secondary
structure of peptides or proteins. An upﬁeld (positive) shift is
characteristic for an α-helix, whereas a downﬁeld (negative) shift is
characteristic for a β-conformation [47] (Fig. 9). Secondary chemical
shift values indicate the presence of α-helical segments in both SDS
and DPC micelles. The helical region lies at the N-terminus in DPC,
while it is shifted towards the region between W3–R6 in SDS.
The solution structure of PFR in SDS was calculated based on 103
distance constraints. The backbone conformation of the peptide forms
a short α-helical turn between residues Trp3 and Arg6 (Fig. 10) in
agreement with secondary chemical shift values. PFR conformation in
SDS micelles is well-deﬁned, with backbone r.m.s.d. of 0.15 Å for the
residues 2–8. The heavy atom r.m.s.d. of hydrophobic residues (Pro1,
Phe2, Trp3, Ile5, Ile7) is only 0.60 Å in comparison to the overall r.m.s.d.
of 1.33 Å. Pro1, Phe2 and Trp3 are clustered together with the side chain
of the N-terminal proline between two aromatic residues. Three N-ft) and in DPC micelles [61] calculated as an average value of H chemical shifts of three
Fig. 10. (a) Solution structure of synthetic amidated PFR in SDS micelles, represented by an ensemble of 20 structures. (b) Backbone conformation of the representative structure of
PFR in complex with SDS. Cationic residues are represented with blue lines.
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dimension and may thus be able to induce defects when inserted into
the bacterial membrane. Arg4 forms the energetically favorable
cation-π interaction with the aromatic group of Trp3, which could
facilitate deeper embedding of PFR into anionic membranes. The side
chains of Arg6, Arg8 and Arg9 are positioned around the axis of the
short helical segment and point to different directions.Fig. 11. (a) Solution structure of synthetic amidated PFR in DPC micelles, represented by an e
PFR in complex with DPC. Cationic residues are represented with blue lines.3.7.2. Structure of PFR peptide in DPC micelles
The structure of PFR in the presence of DPC micelles was
calculated using 79 distance constraints. PFR structure in DPC is
also well deﬁned with a backbone r.m.s.d of 0.38 Å. The backbone
also forms one turn of α-helix, which is however in comparison to
the SDS structure shifted towards the N-terminus and positioned
between residues Phe2 and Ile5 (Fig. 11). The heavy atom r.m.s.d. ofnsemble of 20 structures. (b) Backbone conformation of the representative structure of
Table 1
Structural statistics of PFR ensemble SDS DPC
Distance restraints
Total NOE 97 79
Intraresidual 34 37
Sequential (|i–j|=1) 40 24
Non-sequential (|i–j|N1) 23 18
Structure statistics
Min and max. violations (Å) 0.65, 0.98 0.36, 0.78
Backbone atoms (residues 2–7) 0.15±0.05 0.38±0.29
Heavy atoms (residues 2–7) 1.37±0.37 1.30±0.26
Ramachandran plot quality
Residues in the most favored regions (%) 67.9 53.6
Residues in additional allowed regions (%) 32.1 44.3
Residues in generously allowed regions (%) 0.0 2.1
Residues in disallowed regions (%) 0.0 0.0
Peptide structures were deposited at BioMagResbank under the codes 20012 and 20013
for the structure in SDS and DPC, respectively.
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1.26 Å. Ile5 lies close to Phe2, Arg4 and Arg6 are located close to the
hydrophobic core of the peptide and available for electrostatic
interactions with the phosphate group of micelles, whereas Arg8
and Arg9 in the C-terminal part of the peptide are oriented away from
the hydrophobic core. In contrast to the SDS structure there is no
energetically favorable Trp–Arg interaction, which has been shown to
stabilize the peptide fold in membranes [48].
The comparison between the structure of PFR in SDS and DPC
shows that the peptide is in an α-helical conformation between
residues 3 and 6 in complex with SDSmicelles and between residues 2
and 5 in complex with DPC. The main difference is in the N-terminal
hydrophobic segment. Trp3 in the DPC structure is oriented towards
the Ile7, and Ile5 closer to Phe2, which makes it more compact. This is
evident from the higher solvent exposed surface of the structure in
SDS (1514 vs.1464 Å2), which is mainly due to the increased nonpolar
surface (704 vs. 653 Å2) (Table 1).
4. Discussion
Peptides are in comparison to most antimicrobials still relatively
expensive to produce, which is one of the reasons hindering their
application. The high cost of synthetic peptide synthesis and low yield
of isolation from the natural host stimulates exploration of recombi-
nant production of antimicrobial peptides [22,25,32,49–51]. In our
study we used KSI as a partner protein that is expressed as an
insoluble protein and accumulates in form of inclusion bodies. Most
reported antimicrobial peptides were longer than 20 residues,
however even recombinant production of a 9-residue peptide resulted
in a high yield even without any particular optimization of bacterial
fermentation. Normally, fusion proteins are produced in the form of
inclusion bodies that can be efﬁciently solubilized and recombinantFig. 12. Schematic representation of the orientation of PFR peptide inserted into the membr
perpendicular to the membrane plane, while for longer α-helix of magainin it is parallel to
hydrophobic residues as surface representation.fusion proteins are chemically or enzymatically cleaved to release the
desired antimicrobial peptide product. Protease cleaves with low
efﬁciency on insoluble protein aggregates, and thus researchers have
sought to establish a useful chemical strategy. Previous studies have
reported the release of antimicrobial peptides from fusion partners by
digestion with CNBr, which can cleave peptides at methionine
residues and hydroxylamine which can cleave Asn–Gly peptide
linkages [19]. In our system diluted HCl liberated the peptide from
the fusion protein at high yield and simpliﬁed the isolation procedure.
The recombinant peptide consistently exhibited slightly better
antimicrobial and endotoxin-neutralizing activity as the synthetic
peptide and was indistinguishable by analytical techniques (MS and
HPLC), nevertheless additional amidation of the synthetic peptide
improved the antimicrobial activity due to the increased afﬁnity for
anionic lipids. It has been shown previously that the presence of
additional charge may signiﬁcantly affect the membrane interacting
and biological properties of peptides [52–54]. The selected strategy
requires the N-terminal proline residue of the peptide, which is in fact
even favorable for the selected peptide. We have shown the essential
structural role of the proline residue for the peptide conformation
adopted in the membrane mimetic environment. PFR interacts
preferentially with negatively charged membranes, which provides
its selectivity and high therapeutic index.
The structure of the PFR peptide in SDS and DPC was determined
and in both types of micelles the peptide forms a well-deﬁned
conformation. The peptide in complex with SDS contains α-helical
conformation between residues 3 and 6 and between residues 2 and 5
in complex with DPC. In contrast to most amphipathic α-helical
antimicrobial peptides [55] the amphipathic moment lies along the
helical axis and not perpendicular to it (Fig. 12). This can only be
accomplished because of the small size of the peptide. Clusters of
hydrophobic residues are essential for antimicrobial activity [56],
however a high amount of tryptophan residues increases the
nonspeciﬁc binding to eukaryotic membrane and hemolytic activity
[57,58]. The PFR peptide contains only a single tryptophan residue and
an additional phenylalanine residue, which is responsible for its high
speciﬁcity for anionic membranes and the absence of haemolytic
activity. Alternating Arg–Ile residues in the region 4 to 8 induce
formation of a short helical segment in the peptide. Three
hydrophobic residues at the N-terminus of the PFR peptide form a
cluster, which is more compact in the zwitterionic environment and
has a larger lateral dimension in anionic micelles. The difference in
the charge distribution of PFR in anionic and zwitterionic micelles as
well as arrangement of hydrophobic side chains contributes to the
mechanism of selective discrimination between bacterial and eukar-
yotic membranes. This structural difference is most likely due to the
electrostatic interaction between cationic residues closest to the
membrane surface (Arg4 and Arg6) with negatively charged surface
head groups of anionic vesicles which embeds the peptide deeper
into the micelle, disrupts the interaction of Trp3 with Ile7 and causes
dislocation of the helix. Interaction of guanidinium groups onane (left) and typical α-helical peptide (magainin, right). PFR peptide α-helical axis lies
the plane of the membrane. Side chains of cationic residues are shown as blue sticks as
322 M. Zorko et al. / Biochimica et Biophysica Acta 1788 (2009) 314–323arginine residues with phosphate groups of phospholipids has been
determined before for PG-1 by solid state NMR and proposed to
contribute to the formation of membrane defects [59]. N-terminal
proline, which was introduced because of the recombinant peptide
production approach was essential for the integrity of the structure
and improved the antimicrobial activity. Proline forms an essential
part of the hydrophobic cluster, with many side chain contacts with
side chains of Phe2 or Trp3. The N-terminal hydrophobic cluster of the
PFR peptide has similar function as the short acyl chain of the
lipopeptide [60]. The structures in this report can be used to improve
the design of more selective peptides by enhancing the differences in
local conformational changes caused in zwitterionic and anionic
membranes.
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